Metropolis Healthcare vs Thermo Fisher Scientific: Fair Value & Quality
Both stocks run through our valuation models. Here is how Metropolis Healthcare (METROPOLIS) and Thermo Fisher Scientific (TMO) compare, as of Aug 18, 2026.
As of Aug 18, 2026, Fair Value Calculator sees Metropolis Healthcare as the less overvalued of the two: Metropolis Healthcare trades at ₹551 versus a fair value of ₹363 (-34%), while Thermo Fisher Scientific trades at $586 versus $308 (-47%).
Metropolis Healthcare
METROPOLIS.NSE · INR · Health Care
-34%
upside to fair value
overvalued
Price₹551
Fair Value₹363
Quality70/100
Thermo Fisher Scientific
TMO · USD · Health Care
-47%
upside to fair value
overvalued
Price$586
Fair Value$308
Quality63/100
Get comparisons like this free by email every month: the most undervalued quality stocks.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Metropolis HealthcareThermo Fisher Scientific
Valuation
59.8×P/E (TTM)29.5×
6.86×P/S (TTM)4.41×
7.46×P/B3.74×
28.0×EV/EBITDA20.0×
—PEG1.74×
0.4%Dividend yield0.3%
₹2.00Dividend per share$1.76
Profitability
12%Net margin15%
16%Operating margin18%
13%Return on equity14%
8%Return on assets5%
Growth
23%Revenue growth (YoY)6%
12.8%Avg. growth/yr (3Y)-0.3%
10.5%Avg. growth/yr (5Y)6.7%
Balance & size
—Debt / equity0.67×
$1BMarket cap$199B
healthyGrowth qualityhealthy
Thermo Fisher Scientific leads: 5 to 7 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Metropolis Healthcareof which business quality 70 · market factors 63Thermo Fisher Scientificof which business quality 60 · market factors 67
ProfitabilityMargins and returns on capital today
57
43
Quality GrowthAre margins and returns improving?
67
31
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
52
79
Low VolatilityCalm price path (market factor)
83
69
MomentumPrice trend over the last 3–12 months (market factor)
52
65
52W MomentumDistance to the 52-week high (market factor)
60
67
Net IssuanceBuybacks instead of dilution
79
97
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Metropolis Healthcare
DCF Models₹309
Earnings-Based₹121
Dividend Discount₹17.59
Multiples₹186
Asset-Based₹48.90
Growth DCF₹294
Economic Profit₹114
Growth Earnings₹189
26 of 26 models see the stock below the current price.
Thermo Fisher Scientific
DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341
24 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Metropolis Healthcare
Bear ₹272Fair Value ₹363Bull ₹454
₹551 = current price (white tick)
Thermo Fisher Scientific
Bear $171Fair Value $308Bull $385
$586 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Metropolis Healthcare · Health Care
Quality score70 · Top 25%
Fair value upside-34% · below median
Thermo Fisher Scientific · Health Care
Quality score63 · Top 25%
Fair value upside-47% · below median
Bottom line
As of Aug 18, 2026, Fair Value Calculator sees Metropolis Healthcare as the less overvalued of the two: Metropolis Healthcare trades at ₹551 versus a fair value of ₹363 (-34%), while Thermo Fisher Scientific trades at $586 versus $308 (-47%).
Metropolis Healthcare has the higher quality score (70/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
